Goldman Sachs Starts MAKO Surgical (MAKO) at Conviction Buy, Sees 43% Upside
Tweet
Share
E-mail
Get Alerts MAKO Hot Sheet
Price: $10.54 +0.38%
Rating Summary:
1 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs initiates coverage on MAKO Surgical (NASDAQ: MAKO) with a Conviction Buy list rating and $36 price target, suggesting 43% upside.
The analyst said, "We see MAKO emerging as one of the most compelling growth stories in MedTech, with the potential to transform orthopaedic surgery through the advent of robotic technologies."
Goldman said the company is in the early stages of its growth trajectory, with the long-term outlook driven by further penetration in existing markets like knee replacement, and increasing rates of adoption in new categories, such as hips/extremities.
For more ratings news on MAKO Surgical click here and for the rating history of MAKO Surgical click here.
Shares of MAKO Surgical closed at $23.51 yesterday.
The analyst said, "We see MAKO emerging as one of the most compelling growth stories in MedTech, with the potential to transform orthopaedic surgery through the advent of robotic technologies."
Goldman said the company is in the early stages of its growth trajectory, with the long-term outlook driven by further penetration in existing markets like knee replacement, and increasing rates of adoption in new categories, such as hips/extremities.
For more ratings news on MAKO Surgical click here and for the rating history of MAKO Surgical click here.
Shares of MAKO Surgical closed at $23.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- DA Davidson Starts Everus (ECG) at Buy
- BMO Capital Starts AMD (AMD) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
